Chemical complementation: A definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets

Pharmacology and Therapeutics

Volumn 107, Issue 2, 2005, Pages 212-221

  Vogt, Andreas ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell based assay; Chemical complementation; Drug discovery; Forward Pharmacology; High content screening; Reverse Pharmacology

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2 (2 MERCAPTOETHANOL) 3 METHYL 1,4 NAPHTHOQUINONE; 6 CHLORO 7 (2 MORPHOLIN 4 YLETHYLAMINO)QUINOLINE 5,8 DIONE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; DA 30031; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTERASE INHIBITOR; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROLEPTIC AGENT; NSC 663284; NSC 672121; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; QUINOLINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

COMBINATORIAL CHEMISTRY; DNA LIBRARY; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC COMPLEMENTATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CDC25 PHOSPHATASE; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY;

EID: 21344440488     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.03.002     Document Type: Review

References (60)

1. J. Agnan, C. Korch, and C. Selitrennikoff Cloning heterologous genes: problems and approaches Fungal Genet Biol 21 1997 292 301
2. J.F. Amatruda, J.L. Shepard, H.M. Stern, and L.I. Zon Zebrafish as a cancer model system Cancer Cell 1 2002 229 231
3. L. Augusto-Pinto, C.G. da Silva, D.O. Lopes, A. Machado-Silva, and C.R. Machado Escherichia coli as a model system to study DNA repair genes of eukaryotic organisms Genet Mol Res 2 2003 77 91
4. B. Azizi, E.I. Chang, and D.F. Doyle Chemical complementation: small-molecule-based genetic selection in yeast Biochem Biophys Res Commun 306 2003 774 780
5. B.O. Bachmann, R. Li, and C.A. Townsend Beta-lactam synthetase: a new biosynthetic enzyme Proc Natl Acad Sci U S A 95 1998 9082 9086
6. K. Baker, C. Bleczinski, H. Lin, G. Salazar-Jimenez, D. Sengupta, and S. Krane Chemical complementation: a reaction-independent genetic assay for enzyme catalysis Proc Natl Acad Sci U S A 99 2002 16537 16542
7. F.M. Balis Evolution of anticancer drug discovery and the role of cell-based screening J Natl Cancer Inst 94 2002 78 79
8. M.V. Barone, and S.A. Courtneidge Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src Nat Struct Biol 378 1995 509 512
9. J. Baselga Clinical trials of Herceptin(R) (trastuzumab) Eur J Cancer 37 Suppl 1 2001 18 24
10. M.C. Brezak, M. Quaranta, O. Mondesert, M.O. Galcera, O. Lavergne, and F. Alby A novel synthetic inhibitor of CDC25 phosphatases: BN82002 Cancer Res 64 2004 3320 3325
11. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, and R. Pazdur FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets Oncologist 8 2003 303 306
12. D.W. Cushman, H.S. Cheung, E.F. Sabo, and M.A. Ondetti Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids Biochemistry 16 1977 5484 5491
13. S. Dolma, S.L. Lessnick, W.C. Hahn, and B.R. Stockwell Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells Cancer Cell 3 2003 285 296
14. J. Drews Drug discovery: a historical perspective Science 287 2000 1960 1964
15. B.J. Druker, and N.B. Lydon Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3 7
16. B. Ducommun, G. Draetta, P. Young, and D. Beach Fission yeast cdc25 is a cell-cycle regulated protein Biochem Biophys Res Commun 167 1990 301 309
17. K.S. Elmslie Calcium channel blockers in the treatment of disease J Neurosci Res 75 2004 733 741
18. M. Florio, L.K. Wilson, J.B. Trager, J. Thorner, and G.S. Martin Aberrant protein phosphorylation at tyrosine is responsible for the growth-inhibitory action of pp60v-src expressed in the yeast Saccharomyces cerevisiae Mol Biol Cell 5 1994 283 296
19. T.F. Franke, D.R. Kaplan, and L.C. Cantley PI3K: downstream AKTion blocks apoptosis Cell 88 1997 435 437
20. T.F. Franke, D.R. Kaplan, L.C. Cantley, and A. Toker Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate Science 275 1997 665 668
21. K.L. Gould, S. Moreno, N.K. Tonks, and P. Nurse Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase Science 250 1990 1573 1576
22. J.R. Johnson, P. Bross, M. Cohen, M. Rothmann, G. Chen, and A. Zajicek Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Clin Cancer Res 9 2003 1972 1979
23. R.C. Kane, P.F. Bross, A.T. Farrell, and R. Pazdur Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 8 2003 508 513
24. T.R. Kau, F. Schroeder, S. Ramaswamy, C.L. Wojciechowski, J.J. Zhao, and T.M. Roberts A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells Cancer Cell 4 2003 463 476
25. J.A. Kim Targeted therapies for the treatment of cancer Am J Surg 186 2003 264 268
26. D.P. King, and J.S. Takahashi Forward genetic approaches to circadian clocks in mice Cold Spring Harbor Symp Quant Biol 61 1996 295 302
27. J.S. Lazo, D.C. Aslan, E.C. Southwick, K.A. Cooley, A.P. Ducruet, and B. Joo Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25 J Med Chem 44 2001 4042 4049
28. J. Li, L. Simpson, M. Takahashi, C. Miliaresis, M.P. Myers, and N. Tonks The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene Cancer Res 58 1998 5667 5672
29. R.S. Lokey Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia Curr Opin Chem Biol 7 2003 91 96
30. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 1998 13375 13378
31. T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Schreiber, and T.J. Mitchison Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 286 1999 971 974
32. L.K. McMillan, R.L. Carr, C.A. Young, J.W. Astin, R.G. Lowe, and E.J. Parker Molecular analysis of two cytochrome P450 monooxygenase genes required for paxilline biosynthesis in Penicillium paxilli, and effects of paxilline intermediates on mammalian maxi-K ion channels Mol Genet Genomics 270 2003 9 23
33. M. Miquel Towards the cloning of GLY1 Biochem Soc Trans 28 2000 675 677
34. M. Miquel, C. Cassagne, and J. Browse A new class of Arabidopsis mutants with reduced hexadecatrienoic acid fatty acid levels Plant Physiol 117 1998 923 930
35. M. Monga, and E.A. Sausville Developmental therapeutics program at the NCI: molecular target and drug discovery process Leukemia 16 2002 520 526
36. S. Moreno, P. Nurse, and P. Russell Regulation of mitosis by cyclic accumulation of p80cdc25 mitotic inducer in fission yeast Nat Struct Biol 344 1990 549 552
37. M.P. Myers, J.P. Stolarov, C. Eng, J. Li, S.I. Wang, and M.H. Wigler P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase Proc Natl Acad Sci U S A 94 1997 9052 9057
38. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359
39. P. Russell, and P. Nurse cdc25+ functions as an inducer in the mitotic control of fission yeast Cell 45 1986 145 153
40. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discov Today Targets 10 2005 139 146
41. L.J. Schwimmer, P. Rohatgi, B. Azizi, K.L. Seley, and D.F. Doyle Creation and discovery of ligand-receptor pairs for transcriptional control with small molecules Proc Natl Acad Sci U S A 101 2004 12707 14712
42. D. Sengupta, H. Lin, S.D. Goldberg, J.J. Mahal, and V.W. Cornish Correlation between catalytic efficiency and the transcription read-out in chemical complementation: a general assay for enzyme catalysis Biochemistry 43 2004 3570 3581
43. G.R. Stark, and A.V. Gudkov Forward genetics in mammalian cells: functional approaches to gene discovery Hum Mol Genet 8 1999 1925 1938
44. D. Stehelin, H.E. Varmus, J.M. Bishop, and P.K. Vogt DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA Nat Struct Biol 260 1976 170 173
45. V. Steimle, and B. Mach Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators Curr Opin Genet Dev 5 1995 646 651
46. D. Stokoe, L.R. Stephens, T. Copeland, P.R. Gaffney, C.B. Reese, and G.F. Painter Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B Science 277 1997 567 570
47. A. Tagmount, A. Berken, and N. Terry An essential role of s-adenosyl-l-methionine: l-methionine s-methyltransferase in selenium volatilization by plants. Methylation of selenomethionine to selenium-methyl-l-selenium-methionine, the precursor of volatile selenium Plant Physiol 130 2002 847 856
48. D.S. Tan, M.A. Foley, B.R. Stockwell, M.D. Shair, and S.L. Schreiber Synthesis and preliminary evaluation of a library of polycyclic small molecules for use in chemical genetic assays J Am Chem Soc 121 1999 9072 9087
49. J.P. Th'ng, P.S. Wright, J. Hamaguchi, M.G. Lee, C.J. Norbury, and P. Nurse The FT210 cell line is a mouse G2 phase mutant with a temperature- sensitive CDC2 gene product Cell 63 1990 313 324
50. V.K. Ton, and R. Rao Functional expression of heterologous proteins in yeast: insights into Ca2+ signaling and Ca2+-transporting ATPases Am J Physiol Cell Physiol 287 2004 C580 C589
51. A. Vogt, A. Takahito, A.P. Ducruet, J. Chesebrough, K. Nemoto, and B.I. Carr Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases J Biol Chem 276 2001 20544 20550
52. A. Vogt, K.A. Cooley, M. Brisson, M.G. Tarpley, P. Wipf, and J.S. Lazo Cell-active dual specificity phosphatase inhibitors identified by high-content screening Chem Biol 10 2003 733 742
53. A. Vogt, A. Tamewitz, J. Skoko, R. Sikorski, K.A. Giuliano, and J.S. Lazo The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1 J Biol Chem 280 2005 19078 19086
54. P.M. Voorhees, E.C. Dees, B. O'Neil, and R.Z. Orlowski The proteasome as a target for cancer therapy Clin Cancer Res 9 2003 6316 6325
55. M.J.A. Walker, T. Barrett, and L.J. Guppy Functional pharmacology: the drug discovery bottleneck? Drug Discov Today Targets 3 2005 208 215
56. J.N. Weinstein, T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace Jr., and K.W. Kohn An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343 349
57. Y.E. Whang, X. Wu, H. Suzuki, R.E. Reiter, C. Tran, and R.L. Vessella Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proc Natl Acad Sci U S A 95 1998 5246 5250
58. K. Xia, R.S. Lee, R.P. Narsimhan, N.K. Mukhopadhyay, B.G. Neel, and T.M. Rods Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A Mol Cell Biol 19 1999 4819 4824
59. H. Zhao, and F.H. Arnold Combinatorial protein design: strategies for screening protein libraries Curr Opin Struct Biol 7 1997 480 485
60. Y. Zhao, and H.B. Lieberman Schizosaccharomyces pombe: a model for molecular studies of eukaryotic genes DNA Cell Biol 14 1995 359 371